ONCOLYTICS BIOTECH INC (ONCY) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6823108757
ONCOLYTICS BIOTECH INC financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -28.73 m USD |
| EBIT | -29.07 m USD |
| Net income | -28.76 m USD |
| Diluted EPS – continuing operations | -0.30 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ONCOLYTICS BIOTECH INC
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
More stocks
- J&B International Inc. (4442.TWO)
- iCRAFT Co. Ltd (052460.KQ)
- Sinar Terang Mandiri PT Tbk (MINE.JK)
- HAZER Group Ltd (HZR.AX)
- LanzaTech Global, Inc. (LNZA)
- Nh Prime Reit Co Ltd (338100.KS)
- Inmobiliaria Manquehue S.A (MANQUEHUE.SN)
- Prairie Operating Co. (PROP)
- Daelim B&Co (005750.KS)
- Kutcho Copper Corp (KC.V)
- Dsr Wire (069730.KS)
- Lion Chemtech Co. Ltd (171120.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.